Icagen updates status of ICA-105665 clinical development program

Icagen, Inc. (Nasdaq:ICGND) today provided an update on the status of the clinical development program for ICA-105665. As previously reported, the Company recently suspended enrollment in the photosensitivity study of ICA-105665. As expected, the Company has received notification from the FDA that the IND for ICA-105665 will be placed on clinical hold while final data is being reviewed and next steps are being discussed with the FDA. 

Also as previously reported, the Company has completed the conduct of the multiple ascending dose study in healthy volunteers at daily doses of 500mg and 600mg for a period of seven days. There have been no serious adverse events noted, pending a final review of laboratory data. Analyses of the complete data set from both studies are ongoing.

The Company is focusing the majority of its resources upon its recently renewed collaboration with Pfizer targeting certain sodium channels, including Nav1.7, for the treatment of pain, and its research program targeting TRPA1 for the treatment of pain and inflammation.